Global Capital Network (GCN) features GATC Health as medtech impact brand to consider as a strategic partner for Family Offices, Angel Investors, Venture Capital & PE
Share Article
Recently, GATC & Liquid Biosciences signed a partnership agreement that combines Liquid Biosciences’ evolutionary math and GATC’s artificial intelligence focused on predictive multiomics known as Multiomics Advanced Technology™
Next Generation Medtech Platform
This impactful medical AI technology and JV can significantly reduce drug development costs & personalize healthcare. We want to highlight it as a strategic partnership opportunity to private & institutional capital sources around the world - Josh Bois, CEO Global Capital Network IRVINE, Calif. (PRWEB)